11. The immunoconjugate of claim 10, wherein the immunoconjugate has the formula Ab-(L-D)p, wherein (a) Ab is the antibody of any one of claims 1 to 7:

(b) L is a linker; and

(c) D is a drug moiety, and

(d) p is 1 to 8, and

wherein optionally L is 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), or N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB); and/or D is an auristatin or dolostatin.

12. The immunoconjugate of claim 10 comprising an auristatin or maytansinoid drug moiety (D) wherein the antibody is attached by a linker moiety (L) to D; the compound having Formula I:

$$Ab-(L-D)_p \qquad I$$

where p is 1 to 8; wherein optionally

(i) L has the formula:

$$-A_a-W_w-Y_y-$$

where:

A is a Stretcher unit;

a is 0 or 1;


each W is independently an Amino Acid unit;

w is an integer ranging from 0 to 12;

Y is a Spacer unit covalently attached to the drug moiety; and

y is 0, 1 or 2;

(ii) the immunoconjugate compound has the formula:



(iii) L is SMCC, SPP or SPDB;

21. An immunoconjugate, wherein the immunoconjugate has the formula Ab-(L-D)p, wherein

(a) Ab is the antibody of any one of claims 1 to 7:

(b) L is a linker; and


(c) D is a drug moiety, and

(d) p is 1 to 8, and

wherein optionally L is 6-maleimidocaproyl (MC), valine-citrulline (val-cit), and/or p-aminobenzyloxycarbonyl (PAB), and D is an auristatin;

wherein the antibody of any one of claims 1 to 7 is covalently attached to the drug moiety (D).

22. The immunoconjugate of claim 21, wherein the immunoconjugate compound has the structure:



Ab-MC-vc-PAB-MMAE